1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 1:Patient demographics and indications for temporal bone CT studies
Subjects Age (y)/Gender Indication for CT Patient 1 11/M Mastoiditis Patient 2 16/M Cholesteatoma Patient 3 9/M Cholesteatoma Patient 4 45/M Cholesteatoma Patient 5 33/F Cholesteatoma Patient 6 19 months/M Cholesteatoma Patient 7 7/F Cholesteatoma Patient 8 10/F Cholesteatoma Patient 9 50/M Conductive hearing loss Patient 10 53/F Rule out semicircular canal dehiscence Patient 11 49/F Rule out semicircular canal dehiscence Patient 12 73/M Malignant otitis externa Patient 13 73/M External auditory canal osteoma Patient 14 45/F Conductive hearing loss Patient 15 20 months/F Cholesteatoma